Company news
Agios Pharmaceuticals, Inc. news in 2019
Agios Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020
December 22, 2019
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation
December 15, 2019
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
December 8, 2019
Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
December 8, 2019
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
December 7, 2019
Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer
December 1, 2019
Agios Appoints Jonathan Biller as Chief Legal Officer
November 24, 2019
Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma
November 21, 2019
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
November 12, 2019
Agios Announces Pricing of $256 Million Public Offering of Common Stock
November 6, 2019
Agios Announces Proposed Offering of Common Stock
November 5, 2019
Agios Reports Business Highlights and Third Quarter 2019 Financial Results
October 30, 2019
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors
October 26, 2019
Agios Announces New Commercial Leadership Structure
April 1, 2019
Decks in 2019
- 2019 ASH Investor Reception
Conference · 37 slides · Dec 9, 2019